Discussion: Harnessing AI & Computational Modelling to Optimize Design, Specificity & Efficacy of Induced Proximity Molecules to Support the Development of Tolerable, Selective Therapies

• Optimizing PROTAC linkers & E3 ligase pairing with AI and machine learning tools for enhanced selectivity and potency
• Transforming molecular glue design with AI to predict target engagement, enhance selectivity and minimize off-target degradation
• Employing computational tools and modelling approaches to inform therapeutic strategy across induced proximity modalities

Speakers:

Riccardo Sabatini

Chief Data Scientist

Orionis Biosciences LLC

Jonathan Gilbert

Senior Director - Ecosystem Growth & Contributor Partnerships

Eli Lilly & Co.

Eran Seger

Chief Executive Officer & Co-Founder

Protai

Peter Ung

Principal Scientist

Genentech